文献速递膀胱癌与上尿路尿路上皮癌

临床再分期与肿瘤测序不能准确预测肌层浸润性膀胱癌新辅助化疗反应

Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
PubMed 文献 · Eur Urol · 2020-08-17

本研究回顾性分析2003至2016年接受新辅助顺铂化疗后根治性膀胱切除的肌层浸润性膀胱癌患者,评估化疗后临床再分期(含经尿道切除)及肿瘤测序预测最终病理分期的准确性。结果显示临床再分期诊断准确性差,32%患者被错误降期,且肿瘤突变状态与化疗反应及错误降期率无关。

要点

  • 新辅助化疗后临床再分期(含TUR)诊断准确性差,32%患者被错误降期。
  • 肿瘤测序结果与化疗反应及错误降期率无显著差异。
  • 基于再分期考虑保守管理(如主动监测)需谨慎。

核心结论

  • 新辅助化疗后临床再分期联合或不联合肿瘤突变分析均不能准确评估病理残留病变。

研究设计与样本

  • 回顾性机构数据库研究,纳入2003至2016年接受新辅助化疗后根治性膀胱切除的肌层浸润性膀胱癌患者114例。

主要发现

  • 化疗后临床再分期(含经尿道切除)诊断准确性差,32%患者与最终根治性膀胱切除病理相比被错误降期。

临床怎么用

  • 新辅助化疗后再分期需谨慎,尤其不应基于再分期结果选择主动监测等保守管理策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Standard of care for patients with muscle-invasive bladder cancer (MIBC) includes neoadjuvant cisplatin-based chemotherapy (NAC) followed by consolidative therapy with either chemoradiation or radical cystectomy (RC). Some patients experience robust pathologic responses to NAC, and these have been reported to associate with somatic mutations in specific gene pathways including DNA damage response genes. OBJECTIVE: To evaluate the ability of post-NAC clinical restaging, with or without tumor sequencing, to predict final RC pathologic staging. DESIGN, SETTING, AND PARTICIPANTS: We reviewed our institutional review board-approved institutional database to identify patients with MIBC who underwent NAC followed by RC from 2003 to 2016. Following NAC prior to RC, cystoscopy was performed routinely, with resection of residual visible tumor and/or tumor base (transurethral resection [TUR]). For patients with pre-NAC tumor tissue available, tumor sequencing was performed. Outcome measurements and statistical analysis: Clinical restaging and tumor sequencing were evaluated for their ability to predict the final pathologic stage accurately at RC using chi-square or Fisher's exact test. RESULTS AND LIMITATIONS: A total of 114 patients underwent restaging TUR following NAC and prior to RC. The diagnostic accuracy of post-NAC clinical restaging including TUR was poor, with 32% of patients being downstaged falsely when compared with their final RC pathology. Forty-nine patients had sequencing of pre-NAC tumor tissue, of whom 32 showed at least one mutation of interest. However, NAC responses and rates of false downstaging did not differ significantly according to tumor mutation status. CONCLUSIONS: This study highlights the inaccuracy of post-NAC clinical restaging TUR with or without adjunctive tumor mutation analysis, to assess pathologic residual disease accurately. Caution must be taken when performing post-NAC restaging, especially when considering conservative management strategies such as active surveillance on this basis. Patient summary: Several groups are evaluating whether certain patients, whose bladder cancer responds well to upfront chemotherapy, may be able to forego cystectomy safely. We demonstrate that currently available staging tools and tumor DNA sequencing cannot identify such patients reliably and accurately.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Becker REN, Meyer AR, Brant A, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. 2020. PMID: 32814637. doi:10.1016/j.eururo.2020.07.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。